Fred Meyer, Phd, Cfa

Fred Meyer, Phd, Cfa Email and Phone Number

Entrepreneur in Residence, Institute for Advancing Medical Innovation @ University of Kansas Medical Center
Newton, MA, US
Fred Meyer, Phd, Cfa's Location
Newton Centre, Massachusetts, United States, United States
Fred Meyer, Phd, Cfa's Contact Details

Fred Meyer, Phd, Cfa personal email

n/a

Fred Meyer, Phd, Cfa phone numbers

About Fred Meyer, Phd, Cfa

Life science business development and finance professional with expirience in consulting, investment banking, business development, litigation support and venture capital.Specialties: Skilled at identifying competitive insights to optimize bio-pharma product development and present compelling opportunities for investment, mergers and acquisitions, and licensing partnerships. Extensive experience in project valuation & forecasting, damages assessment, optimizing licensing terms, and scenario analsyses.

Fred Meyer, Phd, Cfa's Current Company Details
University of Kansas Medical Center

University Of Kansas Medical Center

View
Entrepreneur in Residence, Institute for Advancing Medical Innovation
Newton, MA, US
Fred Meyer, Phd, Cfa Work Experience Details
  • University Of Kansas Medical Center
    Entrepreneur In Residence, Institute For Advancing Medical Innovation
    University Of Kansas Medical Center
    Newton, Ma, Us
    View
  • University Of Kansas Medical Center
    Entrepreneur In Residence, Institute For Advancing Medical Innovation
    University Of Kansas Medical Center 2013 - Present
    Kansas City, Ks, Us
    The Institute for Advancing Medical Innovation (IAMI) translates laboratory discoveries into drugs, diagnostics and medical devices. IAMI's focus is cancer, neurologic and rare diseases. Using industry best practices, project plans are developed and executed resulting in development of data packages necessary to validate commercial opportunities. Partnerships and collaborations with industry, academia, government and disease philanthropy organizations are established to bring synergistic resources, to bridge the Valley of Death.
    View
  • Directsync Surgical
    Board Observer
    Directsync Surgical 2023 - Present
    Lawrence, Ks, Us
    Medical device company dedicated to improving the lives of patients who suffer from spine and orthopedic diseases via a patient-powered smart spinal fusion device with Breakthrough Device Designation by the US Food and Drug Administration.
    View
  • Dclk1 Llc
    Business Development Advisor
    Dclk1 Llc 2022 - Present
    Discovering novel agents to treat cholangiocarcinoma
  • Exithera Pharmaceuticals Llc
    Member Of The Board
    Exithera Pharmaceuticals Llc 2014 - Present
    Developing Factor XIa inhibitors for the prevention of stroke and thrombosis.
    View
  • Independent
    Life Science Strategy Advisor
    Independent 2007 - Present
    Assist early to mid stage ventures with valuation and positioning to present compelling partnering and investment opportunities. Entrepreneurial and creative approach to developing ventures to maximize value.
  • Xcovery
    Vp Business & Corporate Development
    Xcovery 2015 - 2016
    Palm Beach Gardens, Florida, Us
    Xcovery’s lead candidate, X-396, is a potent small molecule anaplastic lymphoma kinase (ALK) inhibitor for the treatment of NSCLC where ALK is deregulated. X-396 is up to 10 times more potent than competitive ALK inhibitors and is currently in Phase 2 clinical trials. Importantly, X-396 has shown activity in some ALK mutations that confer resistance to other small molecule ALK inhibitors and in CNS metastases.
    View
  • Tyrogenex
    Vp Business & Corporate Development
    Tyrogenex 2015 - 2016
    Developing X-82, an orally-administered targeted treatment for wet AMD and solid tumors. Currently in Phase 2 clinical trials, X-82 inhibits both the vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR). Preliminary data have shown that orally administered X-82 may provide an alternative delivery option to the eyes of patients with wet AMD. In oncology, X-82’s preliminary studies suggest a toxicity profile that may make X-82 an ideal candidate for combination therapy.
  • Benu Bioventures
    Partner And Co-Founder
    Benu Bioventures 2013 - 2015
    Creating and financing companies to initiate early pharmaceutical clinical development
  • Lipimetix Development Llc
    Vice President Corporate Development
    Lipimetix Development Llc 2010 - 2014
    Joint venture with Capstone Therapeutics (OTCQB: CAPS) to develop Apo E peptide mimetics for refractory hyperlipidemias and acute coronary syndrome
  • Exponential Pharma Partners
    Partner And Founder
    Exponential Pharma Partners 2009 - 2012
    Collaboration with clients to efficiently develop novel early-stage therapeutics in virtual companies from venture creation through clinical proof-of-concept. Operating and deal-making experience used to match entrepreneurs, corporate partners, researchers, contract research organizations, and investors.
  • Larta Institute
    Principal Advisor
    Larta Institute 2009 - 2012
    Los Angeles, Ca, Us
    Worked with NIH-CAP SBIR ventures to commercialize their technologies
    View
  • Apeiron Partners Llc (Formerly Cpp Advisors)
    Principal
    Apeiron Partners Llc (Formerly Cpp Advisors) 2002 - 2008
    Design and finance of licensing partnerships and spin-outs for diverse healthcare clients with drugs in development, discovery platform technologies, and medical devices, including creation of Artisan Pharma with $39m fundraise, based on licensing Western rights to Asahi Kasei’s late stage sepsis drug. Expertise in strategy formulation and valuation work to support M&A. Experience in broad range of therapeutic areas, including numerous cancers, sepsis/anti-coagulants, GI, and cardiovascular diseases. Identification of optimal development path and selection of strategic partners.
  • Needham & Company, Inc.
    Research Associate
    Needham & Company, Inc. 2000 - 2001
    New York, New York, Us
    Equity research covering companies with technology for rapid discovery and development of drug pipelines, including Abgenix, Alkermes, Alteon, Aradigm, Gilead, Human Genome Sciences, Inhale, Millennium, MedImmune, Tularik, Vertex, ViroPharma, and Vitex.
    View
  • Schooner Capital
    Research Analyst
    Schooner Capital 1997 - 2000
    Boston, Ma, Us
    Business development for three international portfolio companies.
    View

Fred Meyer, Phd, Cfa Skills

Biotechnology Venture Capital Commercialization Entrepreneurship Life Sciences Strategy Mergers And Acquisitions Pharmaceutical Industry Lifesciences Corporate Development Strategic Partnerships Clinical Development Start Ups Business Strategy Business Development Strategic Planning Medical Devices Technology Transfer Product Development Drug Discovery Oncology Licensing Valuation Clinical Trials Biopharmaceuticals Due Diligence Drug Development Technology Evaluation Strategic Consulting Business Planning Negotiation Corporate Finance Patents Competitive Intelligence Cro R&d Infectious Diseases Genomics Research And Development Litigation Support Spin Outs Translational Medicine Market Research Financial Modeling Cancer

Fred Meyer, Phd, Cfa Education Details

  • The Ohio State University
    The Ohio State University
    Molecular Genetics
  • University Of Illinois Urbana-Champaign
    University Of Illinois Urbana-Champaign
    Genetics & Development

Frequently Asked Questions about Fred Meyer, Phd, Cfa

What company does Fred Meyer, Phd, Cfa work for?

Fred Meyer, Phd, Cfa works for University Of Kansas Medical Center

What is Fred Meyer, Phd, Cfa's role at the current company?

Fred Meyer, Phd, Cfa's current role is Entrepreneur in Residence, Institute for Advancing Medical Innovation.

What is Fred Meyer, Phd, Cfa's email address?

Fred Meyer, Phd, Cfa's email address is fa****@****zon.net

What is Fred Meyer, Phd, Cfa's direct phone number?

Fred Meyer, Phd, Cfa's direct phone number is +156135*****

What schools did Fred Meyer, Phd, Cfa attend?

Fred Meyer, Phd, Cfa attended The Ohio State University, University Of Illinois Urbana-Champaign.

What skills is Fred Meyer, Phd, Cfa known for?

Fred Meyer, Phd, Cfa has skills like Biotechnology, Venture Capital, Commercialization, Entrepreneurship, Life Sciences, Strategy, Mergers And Acquisitions, Pharmaceutical Industry, Lifesciences, Corporate Development, Strategic Partnerships, Clinical Development.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.